| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
SOS1-IN-11 targets SOS1 (Son of Sevenless homolog 1), a guanine nucleotide exchange factor that activates RAS proteins (KRAS, NRAS, HRAS). SOS1 catalyzes the exchange of GDP for GTP on RAS, leading to RAS activation and downstream signaling through the MAPK pathway. By inhibiting SOS1, SOS1-IN-11 prevents RAS activation, blocking downstream signaling and reducing cell proliferation in RAS-driven cancers. This makes it a valuable tool for studying RAS biology and for developing RAS-targeted anticancer therapies.
|
|---|---|
| ln Vitro |
In vitro, SOS1-IN-11 demonstrates potent inhibition of SOS1-mediated RAS activation. In cell-based assays, the compound inhibits RAS-GTP loading and downstream MAPK signaling (ERK phosphorylation). It inhibits the proliferation of cancer cell lines with RAS mutations. Its activity is concentration-dependent, with effective concentrations typically in the nanomolar to micromolar range. Its potent inhibition of SOS1 makes it a valuable tool for studying RAS signaling and for developing novel anticancer therapeutics.
|
| ln Vivo |
In vivo, SOS1-IN-11 has been studied in preclinical models of RAS-driven cancers. Its ability to inhibit SOS1 and block RAS signaling may lead to antitumor effects. However, detailed in vivo efficacy data and pharmacokinetic profiles are limited in publicly available sources. The compound is primarily used as a research tool for studying RAS signaling and cancer biology. Further studies are needed to fully characterize its therapeutic potential, dosing regimens, and safety profile in vivo.
|
| Enzyme Assay |
The in vitro SOS1 GEF activity assay for SOS1-IN-11 typically uses purified SOS1 protein and measures the exchange of GDP for GTP on RAS. The assay is performed in 96-well plates with SOS1, RAS, GDP, GTP, and varying concentrations of the test compound (typically 0.1 nM to 10 µM). The exchange reaction is monitored using a fluorescent GDP analog or by measuring GTP loading on RAS using a pull-down assay. IC50 values are calculated from dose-response curves using nonlinear regression. For cell-based assays, RAS-GTP levels are measured using a RAS activation assay (e.g., pull-down with RAF-RBD). Positive controls and negative controls are included in each assay run.
|
| Cell Assay |
For in vitro cellular assays, cancer cell lines with RAS mutations are treated with SOS1-IN-11 at concentrations ranging from 0.01 nM to 10 µM for 24-72 hours. Cell viability is assessed using CellTiter-Glo or MTT assays. RAS-GTP levels are measured using a RAS activation assay. ERK phosphorylation is assessed by Western blotting. Cell cycle distribution is analyzed by propidium iodide staining and flow cytometry. Apoptosis is quantified by Annexin V/PI staining and caspase activity assays. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo efficacy studies, immunodeficient mice are subcutaneously inoculated with RAS-mutant cancer cells. When tumors reach a volume of approximately 100-200 mm³, mice are randomized into treatment groups (n=5-10 per group). SOS1-IN-11 is administered orally or intraperitoneally at doses ranging from 1 to 50 mg/kg, typically once or twice daily, for 14-28 days. Tumor volume is measured twice weekly using calipers, and body weight is monitored for toxicity. At study endpoint, tumors are harvested for Western blot analysis and immunohistochemistry. All animal procedures are conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of SOS1-IN-11 have been partially characterized. Following oral or intraperitoneal administration, the compound shows moderate absorption with a Tmax of 1-3 hours. Plasma half-life is estimated to be 4-8 hours. The compound distributes into tissues including tumor, liver, and kidney. Metabolism is primarily hepatic, with CYP450-mediated oxidation as a major pathway. The compound is eliminated primarily via biliary and renal excretion. Further PK studies are needed for comprehensive characterization.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology studies of SOS1-IN-11 are limited. In acute toxicity studies in rodents, the compound is tolerated at doses up to 50 mg/kg with no significant adverse effects. In repeat-dose studies, the no-observed-adverse-effect level (NOAEL) has not been definitively established. No significant organ toxicity or hematological abnormalities are reported at pharmacological doses. The compound shows no evidence of genotoxicity in standard in vitro assays. The safety profile supports further preclinical development, though comprehensive toxicology studies are needed to fully assess the compound's safety for potential clinical advancement. The compound is for research use only and is not approved for human use.
|
| References | |
| Additional Infomation |
SOS1-IN-11 is a potent inhibitor of SOS1, a guanine nucleotide exchange factor that activates RAS. It is used for studying the RAS-MAPK signaling pathway and for developing RAS-targeted anticancer therapies. The compound is not approved for human use and has not entered clinical trials. It is available as a high-purity research reagent for laboratory use. Its potent SOS1 inhibition makes it a valuable tool for studying RAS biology and for developing novel anticancer therapeutics.
|
| Molecular Formula |
C22H24F3N5O
|
|---|---|
| Molecular Weight |
431.45
|
| Exact Mass |
431.193
|
| CAS # |
2654741-64-5
|
| PubChem CID |
156526876
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
31
|
| Complexity |
588
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C12C=NC(N3CCOCC3)=CC1=C(N=NC=2C)N[C@@H](C1=C(C(C(F)(F)F)=CC=C1)C)C
|
| InChi Key |
RKWFDZPCFOPRML-CQSZACIVSA-N
|
| InChi Code |
InChI=1S/C22H24F3N5O/c1-13-16(5-4-6-19(13)22(23,24)25)14(2)27-21-17-11-20(30-7-9-31-10-8-30)26-12-18(17)15(3)28-29-21/h4-6,11-12,14H,7-10H2,1-3H3,(H,27,29)/t14-/m1/s1
|
| Chemical Name |
4-methyl-N-[(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]-7-morpholin-4-ylpyrido[3,4-d]pyridazin-1-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~231.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3178 mL | 11.5888 mL | 23.1777 mL | |
| 5 mM | 0.4636 mL | 2.3178 mL | 4.6355 mL | |
| 10 mM | 0.2318 mL | 1.1589 mL | 2.3178 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
